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Introduction
Consider a magic trick, one that spans millions and mil-
lions of years, performed by a world-class magician known 
as the spliceosome. From a single gene, multiple RNA 
products emerge. The results are intriguing: some of these 
transcripts are almost identical, and others are so unique 
as to exert antagonising functions. However, the trick is 
straightforward: it is a simple unit rearrangement of the 
gene sequence. However, how is such a simple trick per-
formed? Let us unravel the magic of alternative splicing.
Alternative splicing (AS) was first reported in 1977 by 
the laboratories of Richard Roberts and Philip Sharp, who 
observed that mammalian cells infected with adenovirus 
2 in lytic stage produce mRNA sequences complementary 
to non-contiguous DNA segments, as confirmed by elec-
tron microscopic visualisation of these alternative tran-
scripts hybridised with single-stranded fragments of the 
viral genome (Berget et al. 1977; Chow et al. 1977). In the 
following year, Walter Gilbert suggested naming the seg-
ments included in and excluded from the mature mRNAs as 
“exons” and “introns”, respectively (Gilbert 1978).
Splicing in endogenous genes was revealed in the 
beginning of the 1980s with the findings of calcitonin and 
immunoglobulin alternative transcripts in mammals (Liu 
et al. 1980; Tucker et al. 1980; Early et al. 1980a; Rosen-
feld et al. 1981, 1982). The contrasting levels of calcitonin 
expression in rat medullary thyroid carcinoma lines were 
discovered to be related with alternative transcripts later 
observed to originate from the same gene and to encode 
different proteins (Rosenfeld et al. 1981, 1982).
In addition, in the early 1980 s, the interplay between 
pre-mRNAs and the U1, U2, U4, U5, and U6 small nuclear 
ribonucleoproteins (snRNPs) started to be discussed 
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(Lerner et al. 1980; Ohshima et al. 1981; Krainer and Mani-
atis 1985). These snRNPs are core components of a large 
ribonucleoprotein complex required for pre-mRNA splic-
ing, known as the spliceosome (Brody and Abelson 1985; 
Butcher and Brow 2005), that recognises introns through 
cis elements present at exon–intron boundaries (5′ and 3′ 
splice sites) and within introns (branch point sequence and 
polypyrimidine tract) (Reed and Maniatis 1985; Chiou 
and Lynch 2014; Wongpalee and Sharma 2014). As first 
detailed in 1984, pre-mRNA splicing starts with the spli-
ceosome-catalysed cleavage of the phosphodiester bond at 
the 5′ exon–intron junction (5′ splice site) performed by a 
branch point adenosine. This reaction forms an interme-
diary lariat structure that is subsequently liberated by the 
cleavage of the phosphodiester bond at the 3′ exon–intron 
junction (3′ splice site) performed by the free hydroxyl 
group of the 5′ exon, resulting in the joining of the two 
exons (Ruskin et al. 1984; Padgett et al. 1984; Domdey 
et al. 1984; Wongpalee and Sharma 2014) (see Fig. 1).
AS is regulated through exonic and intronic cis-
acting regions called exonic/intronic splicing enhanc-
ers or silencers that are targeted by RNA-binding pro-
teins (RBPs) (Coelho and Smith 2014). These have been 
described as trans-acting splicing regulators and they 
have been divided in heterogeneous nuclear ribonucleo-
protein particles (hnRNPs, Gallinaro et al. 1981), ser-
ine-arginine-rich proteins (SR proteins)—for instance, 
SRSF1 (Krainer and Maniatis 1985; Krämer and Keller 
1985; Krainer et al. 1990), and auxiliary proteins—such 
as SF1 (Krainer and Maniatis 1985) and U2AF (Ruskin 
et al. 1988). Those RBPs may promote or inhibit AS or 
even present opposing regulatory activity depending 
on their binding sites’ location, as illustrated in Fig. 2 
(Goren et al. 2006; Coelho and Smith 2014). Other fac-
tors that are relevant for alternative transcripts to be pro-
duced include the relative location of cis elements, the 
secondary structure of the pre-mRNAs, sequence modi-
fications (such as those resulting from RNA editing), and 
Fig. 1  Spliceosome assembly and splicing reactions. (1) U1 snRNP 
binds to the 5′ splice site (5′ss), whereas the splicing factor 1 (SF1) 
and U2AF proteins bind to the branch point site (BPS), the polypy-
rimidine tract (PPT), and 3′ splice site (3′ss). The interaction between 
U1 and U2 snRNPs results in the formation of the pre-spliceosome. 
(2) The first splicing reaction is performed after the recruitment of the 
U4/5/6 snRNPs through a nucleophilic attack from the adenosine in 
the BPS to the 5′ss of the upstream exon. (3) The intron lariat is then 
formed. The free 3′ hydroxyl group performs a nucleophilic attack 
to the phosphate of the 3′ splice site of the downstream exon. (4) 
Finally, the intron lariat is released and both exons are ligated
Fig. 2  AS regulation by RNA-binding splicing factors. Binding of 
specific splicing factors (SF) to intronic or exonic splicing enhancers 
(ISE and ESE, respectively) promotes the inclusion of the alternative 
exon, whereas binding of given splicing factors to intronic or exonic 
splicing silencers (ISS and ESS, respectively) inhibits the splicing of 
the alternative exon
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epigenetic changes (DNA and RNA methylation, chro-
matin structure and histone modifications, RNA inter-
ference, etc) (Coelho and Smith 2014). The molecular 
mechanisms of spliceosomal assembly and pre-mRNA 
splicing are further detailed in the following reviews: (De 
Conti et al. 2013; Chiou and Lynch 2014; Coelho and 
Smith 2014; Matera et al. 2014; Sperling 2016).
AS may occur in different manners: exon skipping, 
intron retention, mutually exclusive exons, alternative first 
and last exons, alternative 5′ and 3′ splice sites, and alterna-
tive “tandem” 5′ and 3′ untranslated regions (UTRs) (Wang 
et al. 2008; Wagner and Berglund 2014). However, this 
strict categorisation of AS events may not allow to capture 
the landscape of more complex AS events (Sammeth et al. 
2008).
More recently, the ever-improving development and eco-
nomical feasibility of genome and transcriptome sequenc-
ing have facilitated experiments providing novel insights 
into the physiological relevance of AS across species and 
tissues. Such experiments have revealed a higher number 
of alternatively spliced genes and AS events per gene in 
birds and mammals when compared to taxonomic groups 
with fewer cell types, suggesting a link between AS and 
complexity (Chen et al. 2014). Vertebrates indeed display 
a tissue-dependent regulation of AS splicing (Blencowe 
2006; Barbosa-Morais et al. 2012; Merkin et al. 2012) and 
86–88% of human protein-coding genes are reported to 
undergo AS (Wang et al. 2008; Chen et al. 2014).
AS promotes transcriptome diversity and is reported to 
be responsible for autophagy and apoptosis regulation and 
changes in transcription factors, protein localisation signals, 
protein domains (for instance, binding domain changes that 
alter protein interactions) and enzymatic properties (such as 
inactivation or activity modulation of the enzymatic core), 
among others (Kelemen et al. 2013; Paronetto et al. 2016). 
In the same line of evidence, several functions appear to be 
compromised upon dysregulation of AS in multiple human 
diseases (Tollervey et al. 2011; Oltean and Bates 2014; Par-
onetto et al. 2016), as a possible result of changes in cis 
(for instance, through mutations or single nucleotide vari-
ants—SNVs) or trans-acting regulatory elements (through 
alterations in their expression or protein structure, also 
potentially caused by SNVs) (Cartegni et al. 2002).
Aside from AS, there are other transcriptional and post-
transcriptional mechanisms that regulate gene expression, 
such as RNA editing and RNA interference. Particularly in 
primates, a common element between some of these regula-
tion mechanisms is Alu elements, the most abundant trans-
posable sequences in humans (Häsler and Strub 2006; Jeck 
et al. 2013). Alu elements contain cryptic splice sites that 
promote exonisation and are reported to more commonly 
become flanking alternative exons than constitutive exons 
(Lev-Maor et al. 2008; Jeck et al. 2013). Moreover, intronic 
Alu elements may regulate AS by shifting splicing pat-
terns through secondary structure changes to pre-mRNAs. 
These Alu sequences are also usual targets for RNA edit-
ing, reported to modify the conserved splice sites required 
for intron recognition in pre-mRNAs (Rueter et al. 1999). 
Interestingly, the knockdown of the RNA-editing ADAR1 
enzyme in human cells leads to a significant upregulation 
of circular RNA expression (Ivanov et al. 2015) that com-
pete with AS for the spliceosome recruitment, as this is 
required for circular RNA formation (Ashwal-Fluss et al. 
2014).
The identification of genome-wide RNA–protein inter-
actions, along with RNAi screens (Moore et al. 2010), 
have allowed to study splicing-regulatory networks associ-
ated with specific RBPs through high-throughput sequenc-
ing of RNA isolated by crosslinking immunoprecipitation 
(HITS-CLIP, also known as CLIP-Seq) (Licatalosi et al. 
2008) or higher resolution, single-nucleotide CLIP-based 
techniques followed by high-throughput sequencing, such 
as iCLIP-Seq (Rossbach et al. 2014) and PAR-CliP (Hafner 
et al. 2010). These technologies allow to sequence RNAs 
targeted by an RBP of interest and have already been used 
to map, in mouse brains, the RNA–protein-binding sites 
of key splicing regulators such as Nova (Licatalosi et al. 
2008), Rbfox (Weyn-Vanhentenryck et al. 2014), and 
Ptbp2 (Licatalosi et al. 2012). For instance, Ptbp2 has been 
shown to inhibit multiple adult-specific alternative exons in 
murine brains (Licatalosi et al. 2012), and more recently, 
it has been reported that the exclusion of exon 9 in human 
PTBP2-paralog PTBP1 alters the regulatory activity of 
approximately 1500 AS events (Gueroussov et al. 2015).
These and other mechanisms of regulation of AS have 
been extensively studied in different physiological and dis-
ease contexts, revealing an additional level of tissue-spe-
cific post-transcriptional control characterised by tight spa-
tio-temporal modulation of gene expression. This review 
will elaborate on the critical contribution of the AS pro-
gram to the high levels of transcriptomic complexity and 
functional specificity in human development and physiol-
ogy. Moreover, it approaches AS changes in the context of 
host–pathogen interactions, neurodegeneration, cancer, and 
other pathological conditions. Finally, it concludes with a 
discussion on therapeutic approaches targeting AS.
Alternative splicing in the nervous system
The human brain contains over a trillion neurons that are 
connected to each other through highly specific and con-
voluted patterns of synaptic connections (Zaghlool et al. 
2014). Due to its intrinsic complexity, the mammalian 
nervous system has evolved to generate a vast protein 
diversity by the extensive use of AS (Ule et al. 2006). In 
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fact, AS is more abundant in the brain, comparing with 
other organs (Barbosa-Morais et al. 2012). Moreover, the 
nervous system has a specific way of regulating its AS 
programme based on the observations that some RBPs 
are uniquely expressed in neuronal populations, suggest-
ing that they may control cell type and synapse-specific 
functions (Traunmüller et al. 2016). Therefore, AS in the 
brain must be tightly regulated, since the slightest change 
in splicing outputs can have profound effects in several 
important neuronal aspects such as neurogenesis and syn-
aptic function (Lipscombe and Diane 2005).
During neurogenesis, AS patterns vary considerably. 
In the onset of neuronal differentiation, these switches of 
patterns are mainly regulated by changes in the expres-
sion of PTB (polypyrimidine tract binding) proteins, 
namely, PTBP1 and PTBP2, and SRRM4 (serine/arginine 
repetitive matrix protein 4) (Raj et al. 2015; Vuong et al. 
2016), as illustrated in Fig. 3a.
Fig. 3  Role of splicing fac-
tors during neurogenesis and 
neuron maturation. A PTBP1 
is responsible for repress-
ing the activation of neuronal 
genes and is highly expressed 
in neuronal stem cells and 
neuronal progenitor cells. Upon 
differentiation, PTBP1 becomes 
downregulated, allowing the 
induction of PTBP2 and PBX1 
that will activate neuronal 
genes. SRRM4 also becomes 
expressed during neuronal 
differentiation and contributes 
to it by inactivating REST, a 
repressor of activation of neu-
ronal genes. After the neurons 
become mature, the levels of 
PTBP2 decrease, giving rise 
to an adult neuronal splicing 
programme. NMD nonsense-
mediated decay, NPC neural 
progenitor cell. B Once the neu-
ronal cell fate commitment is 
achieved, neurons can migrate 
to generate the laminar structure 
of the brain. NOVA2 is a splic-
ing factor particularly important 
for the cortical lamination 
since it regulates AS of Dab1 to 
promote neuronal migration. VZ 
ventricular zone, SVZ subven-
tricular zone, IZ intermediate 
zone, CP cortical plate. C For 
the maturation process, neurons 
form synapses. This process is 
equally controlled by splicing 
factors, namely, KHDRBS2 that 
regulates neurexins (presynaptic 
cell-adhesion proteins), which 
are essential for synapse forma-
tion and transmission, and the 
NOVA family that regulates AS 
of neurotransmitter receptors
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PTBP1 is expressed at high levels in neural stem cells 
and neural progenitor cells (NPC) but, upon neuronal dif-
ferentiation, it becomes repressed, allowing the induction 
of PTBP2 expression, which in turn promotes NPC differ-
entiation in postmitotic neurons (Li et al. 2014). In fact, it 
was shown that PTBP1 depletion in fibroblasts is enough 
to drive them towards a neuronal phenotype (Xue et al. 
2013). Once the neurons become mature, the expression of 
PTBP2 is reduced, giving rise to an adult neuronal splicing 
programme (Linares et al. 2015). Together, the PTBP1 and 
PTBP2 interplay is thought to be responsible for 25% of 
neuron-specific AS events (Zaghlool et al. 2014) by coor-
dinating splicing programmes through the use of a large 
set of target exons that display a range of responsiveness 
dependent on their levels of expression (Keppetipola et al. 
2012; Linares et al. 2015). For instance, PTBP1 represses 
PBX1 (pre-B-cell leukaemia homeobox 1) exon 7, which 
creates an embryonic stem cell form of PBX1 that does not 
affect neuronal genes (Linares et al. 2015). Once PTBP1 
is removed, the exon is included forming a PBX1 isoform 
able to promote the activation of neural genes. Another tar-
get of PTBP1 is PTBP2 exon 10, which is skipped when 
PTBP1 is expressed, producing a PTBP2 isoform that is 
degraded by nonsense-mediated decay (Spellman et al. 
2007).
As mentioned above, the brain-specific SRRM4 also 
plays an important role during neurogenesis. Also known as 
nSR100, it targets several brain-specific exons in genes that 
are critical for nervous system development (Calarco et al. 
2009). In fact, one of the most important roles of SRRM4 
is the negative regulation of a transcriptional repressor of 
genes required for neurogenesis (REST). It promotes AS of 
REST transcripts to produce the REST4 isoform that has 
a reduced repressive activity, thus activating expression of 
REST targets in neural cells (Raj et al. 2011; Norris and 
Calarco 2012). Moreover, nSR100 directly outcompetes 
widespread neural exon repression by PTBP1 during early 
stages of neurogenesis (Raj et al. 2014).
Once the neuronal cell fate commitment is achieved, 
neurons and axons can migrate in a coordinated time and 
space manner to generate the laminar structure of the 
brain (Iijima et al. 2016). Two families of RBPs, NOVA 
(i.e. NOVA1 and NOVA2) and RBFOX (i.e. RBFOX1, 
RBFOX2, and RBFOX3), were linked to this neuronal 
development stage. NOVA1 is exclusively expressed in the 
subcortical regions and in postmitotic neurons of the cen-
tral nervous system whereas NOVA2 is primarily expressed 
in the neocortex (Yano et al. 2010). In general, NOVA was 
shown to be important for the neuronal migration of mitotic 
progenitors and differentiated interneurons in the spinal 
cord as well as for axon outgrowth and guidance (Leggere 
et al. 2016). Moreover, NOVA2 was displayed as being 
important for cortical lamination since its absence causes 
the abnormal inclusion of the exon 7b and 7c in the DAB1 
transcript, a component of the Reelin pathway that controls 
cortical neuronal migration and lamination (Yano et al. 
2010; Norris and Calarco 2012) (see Fig. 3b).
Regarding the RBFOX family, RBFOX1 is expressed in 
neurons, heart and muscle and its absence in mouse, espe-
cially of isoform Rbfox1-iso2, causes defects during cor-
ticogenesis due to impairments in migration, axon growth 
and dendrite development of excitatory neurons (Hamada 
et al. 2015). RBFOX2, besides being expressed in all the 
aforementioned tissues, is also expressed in the embryo, 
hematopoietic stem cells and embryonic stem cells (ESCs) 
and plays a more critical role in the development of the 
cerebellum (Gehman et al. 2012). In fact, the absence of 
RBFOX2 affects the cerebellum by reducing its size and 
causing loss of foliation (Gehman et al. 2012). Moreover, 
RBFOX3 has been shown to be exclusively expressed in 
neurons and important for the promotion of neuronal differ-
entiation of postmitotic neurons (Kim et al. 2013). Indeed, 
one of RBFOX3 targets is Numb, a crucial gene for the 
central nervous system (CNS) development since its loss 
of function in mice promotes deficiency in cranial neural 
tube closure and premature neuron production in the fore-
brain (Zhong et al. 2000; Kim et al. 2013). RBFOX1 is also 
responsible for the downregulation of RBFOX2 expression 
in RBFOX3-expressing cells (Dredge and Jensen 2011; Lin 
et al. 2016).
After the differentiation and migration processes are 
accomplished, neurons undergo a long period of formation 
and maturation of synapses. AS regulates crucial presyn-
aptic cell-adhesion proteins for this stage named neurex-
ins that are essential for synapse formation and transmis-
sion (Treutlein et al. 2014). This regulation is performed 
through the use of KHDRBS2 (KH-domain-containing, 
RNA-binding, signal-transduction-associated protein 2) 
(Iijima et al. 2014) (see Fig. 3c).
Other RBPs have also been shown to be important for 
synapse maturation. For instance, PTBP1 and PTBP2 are 
involved in synaptic maturation (Li et al. 2014) by regu-
lating the expression of a scaffolding protein, PSD-95, that 
plays a key role during the synaptic maturation and plastic-
ity of excitatory neurons (Zheng et al. 2012). NOVA seems 
to be equally relevant for the maturation of synapses as it 
regulates exons from genes that encode for neurotransmit-
ter receptors or proteins that regulate the neurotransmitters 
release (Ule et al. 2005) (see Fig. 3c). ELAVL, MBNL, 
RBFOX1 and RBFOX3 are also reported as being impor-
tant for the regulation of synaptic function (Wang et al. 
2015c; Vuong et al. 2016; Lara-Pezzi et al. 2016). All this 
evidence supports the crucial role of AS in the different 
stages of the neuronal development in providing molecular 
tools necessary for the complex activity of the central nerv-
ous system.
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Consistently with the described importance of AS in 
brain development and function, AS impairments are 
already known to be involved in several neurological dis-
eases (Chabot and Shkreta 2016). Irimia and colleagues 
showed that most neuronal microexons (3–27 nucleotides) 
are misregulated in autism spectrum disorder and that this 
misregulation is linked to the downregulation of SRRM4 
(Irimia et al. 2014). ELAVL2 was also shown to regulate 
transcripts related to autism (Berto et al. 2016). Muta-
tions in RBFOX1 were likewise linked to autism, as well 
as with mental retardation and epilepsy (Mills and Michal 
2012; Lee et al. 2016). Moreover, widespread alterations 
in splicing patterns of ion channel genes were linked to 
epilepsy and Alzheimer disease (Heinzen et al. 2007). In 
fact, AS was also shown to be playing a role in neurode-
generative disorders. Mutations in two RNA/DNA-binding 
proteins, TDP-43 and FUS/TLS, were found to be related 
with amyotrophic lateral sclerosis and frontotemporal 
lobar degeneration (Polymenidou et al. 2012; Cookson 
2017). However, their role in these diseases seems to be 
complex and is not completely clear. Alzheimer’s disease-
relevant genes, such as APP, TAU or APOE4, are known 
to undergo AS (Love et al. 2015) and shifts in the ratio 
of different types of SNCA isoforms are thought to play a 
role in Parkinson’s disease pathogenesis (La Cognata et al. 
2015). Other splicing-related, not directly causative genes 
implicated in Parkinson’s disease, such as SRRM2, showed 
likewise condition-specific alterations in splicing regulation 
(La Cognata et al. 2015).
The frequent association of RNA regulatory dysfunction 
with neurological disorders demonstrate the relevance of 
AS in the nervous system (Nussbacher et al. 2015). How-
ever, its function as well as the mechanisms that underlie 
the regulation of splicing therein are still not fully eluci-
dated. It is, therefore, necessary to expand our knowledge 
on those areas to improve therapies and diagnostic methods 
for neurological diseases.
Alternative splicing in gametogenesis
Spermatogenesis represents a continuous androgen-
dependent developmental process defined by extensive 
transcriptional activity and reprogramming which is highly 
influenced by the interaction between germ and somatic 
cells. This unique regulatory mechanism guarantees faith-
ful transition of spermatogonial stem cells throughout the 
meiosis process to produce haploid spermatocytes, as well 
as their subsequent differentiation into round spermatids 
and finally into functional spermatozoa.
In agreement with the notion that substantial modifi-
cations occur in the regulation of gene expression dur-
ing this process, AS has been shown to be a predominant 
phenomenon in the testis. In fact, brain and testis are the 
anatomic sites where the highest levels of exon skipping 
events and the most specific expression of splicing-related 
genes take place (Yeo et al. 2004; Grosso et al. 2008; Bar-
bosa-Morais et al. 2012). This testis-specific signature was 
observed in human, chimpanzee and mouse and includes 
the organ-specific expression of several splicing regulators 
such as SF3A2, SRPK1, SRPK2, as well as core snRNP 
components.
However, a considerable number of splicing events 
in human testis are not conserved in other closely related 
organisms and many of them account for non-functional 
protein products by introducing premature stop codons in 
transcripts’ sequences. Based on these observations, it has 
been proposed that part of the testis-specific splicing may 
represent “background” noise induced by high levels of cell 
proliferation, decrease of quality control or unspecific fluc-
tuations in the expression of splicing regulators (Elliott and 
Grellscheid 2006). Nevertheless, several lines of evidence 
provide support for a relevant contribution of splicing regu-
lation in spermatogenesis and fertility.
A classical example is the splicing-dependent rever-
sal of the transcription factor CREM from a transcrip-
tional repressor in premeiotic germ cells to a potent tran-
scriptional activator in the pachytene spermatocyte stage 
(Foulkes et al. 1992). This functional switch regulates the 
expression of genes related to the differentiation of mature 
spermatozoa and, concordantly, infertile male patients with 
round spermatid maturation arrest express only the repres-
sor version of CREM in the testis (Peri and Serio 2014). 
Further analyses have revealed that AS also plays critical 
roles during specific stages of sperm cell maturation, such 
as the biogenesis of the acrosome, an exocytotic vesi-
cle present on the apical surface of the sperm head that is 
essential for the fusion with the oocyte plasma membrane. 
Acrosome formation is modulated by the two variants of 
proacrosin-binding protein ACRBP, the wild-type ACRBP-
W and the intron 5-retaining splice variant ACRBP-V5, 
which are generated by AS of the Acrbp gene (Kanemori 
et al. 2013). A study in mouse epididymal sperm showed 
that ACRBP-V5 participates in the formation of the acro-
somal granule into the centre of the acrosomal vesicle 
during early spermiogenesis, whereas ACRBP-W main-
tains proacrosin as an enzymatically inactive zymogen in 
the acrosome until acrosomal exocytosis in later stages 
(Kanemori et al. 2016). Moreover, it was recently shown 
that splice variants of the fibroblast growth factor receptors 
(FGFRs), known to regulate cell migration via PI3 K/Akt 
and MAPK/ERK signalling (Pintucci et al. 2002; Francav-
illa et al. 2013), are expressed in human testis and localise 
to the acrosomal region and the flagellum (Saucedo et al. 
2015). Importantly, FGFRs shown activation in response 
to the FGF2 ligand, revealed by increased flagellar FGFR 
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phosphorylation, which appeared associated with the acti-
vation of extracellular signal-regulated kinase ERK and Akt 
signalling pathways, as well as to increased sperm motility 
and sperm kinematics. It is therein hypothesised that FGF2, 
known to be present in the endometrium, the oviduct and in 
the oocyte vicinity (Malamitsi-Puchner et al. 2001), could 
bind to FGFR splice variants in the sperm acrosome to reg-
ulate fertilisation-related events.
A recent RNA-seq study evidenced a prominent repro-
gramming of the splicing environment during male meiosis 
in mice, identifying more than a hundred splicing switches, 
including skipping of exon 2 in the ODF2/Cenexin tran-
script, and mutually exclusive exons in the Ate1 gene 
(Schmid et al. 2013). ODF2 has been involved in a func-
tional switch as microtubules organiser, moving from the 
centriole in somatic cells to the sperm tail in post-meiotic 
cells, whereas Ate1 encodes for a histone methyltransferase 
proposed to have important physiological roles in sper-
miogenic chromatin remodelling (Lambrot et al. 2012). 
Global changes in the levels of splicing regulators were 
also observed during spermatogenesis in this and other 
studies, including the upregulation of germ cell-specific 
Sam68, T-STAR, hnRNPGT, and RBMY proteins (Ver-
net and Artzt 1997; Venables et al. 2000, 2004; Paronetto 
et al. 2006) as well as alterations in the expression of non-
germ cell-specific splicing factors, such as the downregula-
tion of PTBP1, MBNL1, MBNL2, and hnRNPA1, and the 
upregulation of PTBP2/nPTB, BCAS2/SPF27, Tra2b, and 
the CUGBP ELAV-like proteins CELF1 (previously shown 
to be essential for normal spermatogenesis in mice) and 
CELF2 (Kress et al. 2007; Lambrot et al. 2012; Schmid 
et al. 2013; Liu et al. 2017).
The finding that members of the CELF protein group, 
including CELF1 and CELF2, were upregulated, while 
muscleblind proteins MBNL1 and MBNL2 appeared tran-
scriptionally repressed during meiosis seems to be in agree-
ment with the previously described antagonistic activity 
of CELF and muscleblind proteins (Kalsotra et al. 2008; 
Wang et al. 2015a; Solana et al. 2016). Moreover, the 
authors speculate that PTBP2 may functionally replace 
PTBP1 during meiosis, similar to what has been observed 
during neurogenesis (Boutz et al. 2007; Licatalosi et al. 
2012), and suggested a suchlike replacement strategy of 
RBMX with RBMXL2/hnRNPGT. Consistently with these 
findings, an isoform-level expression profiling of genes 
located at the azoospermia factor (AZF) region at the Y 
chromosome identified 11 novel transcripts involved in 
human male infertility, including RBMX2, RBMXL1-1, 
and RBMXL1-2 (Ahmadi Rastegar et al. 2015). The same 
study proposed a diagnostic splicing-related signature that 
can be potentially used to effectively discriminate between 
premeiotic maturation arrest, Sertoli-cell-only syndrome, 
nonobstructive azoospermia, and normal testicular tissues, 
highlighting the importance of exploring spliced variants of 
candidate genes in spermatogenic failure.
RBM5 was also recently identified as a novel male germ 
cell splicing factor required for spermatid differentiation 
and male fertility (O’Bryan et al. 2013; Bao et al. 2014). 
A missense mutation in the second RNA recognition motif 
(RRM) of RBM5 appeared to induce shifts in its isoform 
ratios, as well as production of novelly spliced transcripts 
in putative RMB5 target genes, including members of the 
aforementioned MAPK/ERK signalling pathway (Xia and 
Yan Cheng 2005). Mutant mice exhibited an azoospermia 
phenotype (no sperm in the ejaculate) due to spermatid dif-
ferentiation arrest, germ cell sloughing and apoptosis.
The growing interest in the AS regulatory mechanisms 
during spermatogenesis has allowed the identification of 
previously uncharacterised splicing-related proteins, which 
appeared involved in the disruption of round spermatid 
differentiation and male sterility. The testis-specific mam-
malian BET gene Brdt for instance, known to function as a 
transcriptional regulator, was associated with the modula-
tion of gene expression as part of the splicing machinery, 
through the regulation of 3′-UTR processing in round sper-
matids in mice (Berkovits et al. 2012). Similarly, RANBP9, 
a member of the Ran-binding protein family (RanBP) 
involved in nucleocytoplasmic transport, was also found to 
associate in mice with numerous splicing factors including 
SF3B3, hnRNPM, PABPC1, and PABPC2, and has been 
involved in the AS of more than 2,300 mRNAs in spermat-
ocytes and round spermatids (Bao et al. 2014).
Interestingly, a recent study has revealed an interplay 
between AS regulation and higher order chromatin organi-
sation during spermiogenesis, based on the analysis of the 
chromatin-binding protein MRG15 (Iwamori et al. 2016). 
Human MRG15 is known to recruit PTBP1 to intronic 
splicing silencer elements near exons through its binding 
to methylated H3K36 (Luco et al. 2010). In mouse sper-
matids, MRG15 was found also to colocalise with PTBP1 
and PTBP2 at H3K36me3 sites and conditional knock-out 
males lacking MRG15 showed spermatogenic arrest at 
the round spermatid stage, concomitant with an increase 
in intron retention and exon skipping events, suggest-
ing that MRG15 may be a key regulator of splicing dur-
ing spermiogenesis. To note, haploid spermatids experi-
ence a profound reorganisation and compaction of their 
chromatin, where a histone-based nucleosomal structure 
is extensively substituted by a protamine-based structure, 
a process that requires incorporation of testis-specific his-
tone variants, post-translational histone modifications, 
chromatin-remodelling complexes, and transient formation 
of DNA breaks. Thus, the finding that AS may be coupled 
to histone dynamics during round spermatid stage leads to 
the proposal that regulation of pre-mRNA splicing by his-
tone modifications can be an important conceptual element 
1022 Hum Genet (2017) 136:1015–1042
1 3
to understand spermatogenesis and epigenetic disorders 
in male infertile patients. In Fig. 4, a graphical represen-
tation of spermatogenesis and the associated AS program 
described in this section is depicted.
Finally, the role of AS in human infertility may not be 
restricted to the spermatogenesis process. The androgen 
receptor (AR), for instance, is a steroid receptor transcrip-
tion factor playing important roles in human reproduction. 
Multiple AR AS variants have been involved in andro-
gen insensitivity syndrome and associated male infertil-
ity (Dehm and Tindall 2011; Iwamori et al. 2016), but 
also in polycystic ovary syndrome, one of the most com-
mon causes of female infertility (Wang et al. 2015b). The 
mammalian follicle-stimulating hormone receptor (FSHR) 
gene encodes distinct splice variants resulting from exon 
skipping events that correlate with low response to ovar-
ian stimulation with exogenous follicle-stimulating hor-
mone (FSH) (Karakaya et al. 2014). These data suggest 
that alterations in the AS programme regulating hormone 
receptor pathways may be an important pathogenic mecha-
nism in infertility. Further studies are required not only to 
validate in humans the abundant evidence for AS modula-
tion observed during mouse spermatogenesis, but also to 
comprehensively characterise the global splicing regulatory 
mechanisms governing human germ cell differentiation and 
reproduction.
Alternative splicing in muscular tissues
The functional unit of myofibrils in striated muscular tis-
sues is the sarcomere (Fig. 5a), a complex structure formed 
of overlapping protein filaments, whose dynamic sliding 
enables the shortening of the muscle fibre, ensuring con-
traction (Seeley et al. 2006; Squire 2016). Several studies 
reported that AS may play a fundamental role on the mas-
sive transcriptomic remodelling required during the transi-
tion from embryonic to adult muscle and for the dynamic 
functions required for contractile proteins in sarcomeres 
to achieve the demands of muscular tissues, such as con-
traction and force generation (Kalsotra et al. 2008; Giudice 
et al. 2014; Wang et al. 2016).
Muscle was one of the first tissues reported to have 
a specific pattern of AS (Llorian and Smith 2011). 
MBNL and CELF protein families have been consist-
ently described as regulating muscle-specific AS events. 
Fig. 4  Graphical representation of spermatogenesis and its associ-
ated AS program. Temporal expression of key splicing factors and 
splice variants during meiotic division and spermatid maturation 
is represented by violet gradients. Bottom gradient panel shows the 
upregulation of the non-germ cell-specific splicing factors SPF27, 
RBM5, PTBP2, Tra2b, CELF1, and CELF2 and the germ cell-spe-
cific splicing factors (Sam68, T-STAR, hnRNPGT, and RBMY). Top 
gradient panel shows downregulation of the splicing factors PTBP1, 
MBNL1, MBNL2, and hnRNPA1. AS of the mRNA of the transcrip-
tion factor CREM induces a functional switch from a transcriptional 
repressor in premeiotic cells to a transcriptional activator in the 
pachytene spermatocyte stage. Studies in mouse suggest that two 
splice variants of the proacrosin-binding protein ACRBP, ACRBP-
V5, and ACRBP-W, participate in transport/packaging of proacrosin 
into acrosomal granules during spermiogenesis and in the promotion 
of acrosin release from the acrosome during acrosomal exocytosis, 
respectively. Similarly, splice variants of the fibroblast growth factor 
receptors (FGFRs) are expressed in spermatocytes and round sperma-
tids and localise to the acrosomal region and the flagellum of mature 
sperm cells in humans
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MBNL1 typically modulates AS in muscle by repress-
ing or promoting the inclusion of exons when binding 
to their upstream introns or downstream introns, respec-
tively (Goers et al. 2010; Barash et al. 2010; Llorian and 
Smith 2011). The AS pattern during muscle develop-
ment is regulated, among other factors, by an antagonism 
between the increased levels of MBNL1 and decreased 
expression of CELF1 (Pistoni et al. 2010) (see Fig. 5). In 
fact, a study with transgenic mice replicating the embry-
onic expression levels of CELF1 and MBNL1 in adult 
heart reproduces most of the embryonic splicing profile 
(Kalsotra et al. 2008). Other RBPs have been reported 
to regulate muscle-specific AS, such as RBFOX1 and 
polypyrimidine tract binding proteins, and other pairs 
of protein families with antagonistic functions in AS 
regulation have been established, such as CELF and 
PTB (Charlet et al. 2002; Sureau et al. 2011; Llorian and 
Smith 2011; Lara-Pezzi et al. 2013).
Most of the reported AS-associated alterations in muscu-
lar diseases are related to the loss of adult AS programmes 
and mimicking of the embryonic/developing splicing pro-
file, which is incompatible with function of developed tis-
sues, namely, in the heart (Ho et al. 2004; Lee and Cooper 
2009; Giudice et al. 2014). The postnatal development 
of the vertebrate heart involves extensive physiological 
changes to cope with the requirements of its mature func-
tion and AS has been reported to greatly contribute to the 
associated transcriptomic alterations (Kalsotra et al. 2008; 
Giudice et al. 2014). Moreover, AS is known to contribute 
to heart function in the regulation of important processes 
Fig. 5  Alternative splicing of sarcomeric and membrane receptor 
proteins tunes muscular function. a Muscle contraction is achieved 
through the sliding between thin (rich in actin) and thick (rich in 
myosin) myofilaments of the sarcomere, shortening its length. Diver-
sity of isoforms of sarcomeric proteins (such as titin, tropomyosin or 
troponin) required for tissue- or developmental stage-specific func-
tions in muscular tissues arises by alternative splicing (sarcomere 
structure based on (Seeley et al. 2006)). b RNA-binding proteins 
MBNL1 and CELF1 are two major regulators of muscle-specific AS 
whose levels shift during the transition from embryonic to mature tis-
sue. The calcium equilibrium needed for contraction of muscle cells 
is achieved by the coordinated activities of  Ca2+ receptors at the 
membrane of the sarcoplasmic reticulum. Developmentally regulated 
AS of the sarcoplasmic/endoplasmic reticulum ATPase  Ca2+ trans-
porting (SERCA2) and ryanodine receptors (RyR) shapes calcium 
handling, controlling sarcomere contraction. Titin isoforms with dif-
ferent levels of stiffness change their relative abundance ratio in mus-
cle cells during the transition from embryonic to adult tissue, altering 
myocardial compliance. The levels of the larger and more compliant 
titin isoform N2BA decrease with development, while the smaller and 
stiffer isoform N2B levels increase in mature and healthy muscle tis-
sue. Troponin, one of the thin filament proteins, tunes the interactions 
between actin and myosin. MBNL1 and CELF1 regulate the inclu-
sion of exon 5 of the cardiac troponin (cTNT) pre-mRNA by binding 
in the upstream or downstream intron, respectively. Tissue and devel-
opmental stage specificity of tropomyosin is achieved through the 
usage of alternative promoters and mutually exclusive exons of three 
of the four tropomyosin mammalian genes. In the case of the tropo-
myosin α gene, two alternative first exons and three sets of mutually 
exclusive exons contribute to the variability of tropomyosin isoforms
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such as calcium handling and sarcomere contraction (Lara-
Pezzi et al. 2013).
The complexity of muscular tissues arises from the 
diversity required for the function of sarcomeric contractile 
proteins. In the sarcomere, myosin thick myofilaments are 
able to cross-link with actin thin myofilaments upon bind-
ing of  Ca2+ to binding sites in troponin molecules, coupled 
to thin filaments. The increase in  Ca2+ levels is triggered 
by an action potential at the neuromuscular junction that is 
propagated to the whole cell through the sarcolemma into 
T-tubules, structures that ultimately lead to the release of 
 Ca2+ by the sarcoplasmic reticulum. Accurate  Ca2+ bal-
ance is required for concerted contraction and, therefore, of 
utmost importance for correct muscular function. Calcium 
handling is also dependent on the ion channels that enable 
its uptake to the sarcoplasm from the sarcoplasmic reticu-
lum (Seeley et al. 2006). The transition from embryonic 
to adult cardiac muscle tissue is accompanied by isoform 
shifts in many of the proteins involved in the sarcomere 
function and the excitation–contraction coupling (Lara-
Pezzi et al. 2013; Zhu et al. 2016).
Thin filament proteins, such as cardiac troponin T 
(cTNT), undergo AS under the regulation of MBNL1 and 
CELF2. In adult cardiac muscle, an increased number of 
MBNL1 protein molecules bind to the upstream intron 
of cTNT, inhibiting the binding of essential spliceoso-
mal components, leading to the skipping of exon 5 (Warf 
et al. 2009). In embryonic cardiac muscle, on the contrary, 
inclusion of exon 5 of cTNT is enhanced by the action of 
CELF2 in promoting and stabilising the binding of the spli-
ceosomal component U2 snRNP, after binding to the down-
stream intron (Goo and Cooper 2009). Isoform diversity of 
tropomyosin (another thin filament protein) is expanded 
by the use of alternative promoters and mutually exclusive 
exons from the four tropomyosin genes (Tropomyosin α, β, 
γ, and δ), tuning actin/myosin interaction in sarcomeres in 
a developmental stage- and cell-specific manner (Gunning 
et al. 2005; Lara-Pezzi et al. 2013) (Fig. 5b).
The balance of  Ca2+ inside the muscle fibre is controlled 
by a tight orchestration of membrane receptors’ function. 
One of the processes involved in muscle contraction is the 
release of  Ca2+ from the sarcoplasmic reticulum through 
the ryanodine receptors (RyR). Two developmentally reg-
ulated alternatively spliced variants of the human cardiac 
RyR receptor (RYR2) have been reported to affect car-
diomyocyte susceptibility to undergo apoptosis by differ-
ential regulation of nuclear and cytoplasmic  Ca2+ release 
(George et al. 2007). The sarcoplasmic/endoplasmic reticu-
lum ATPase  Ca2+ transporting, SERCA2, is responsible 
for pumping  Ca2+ back into the sarcoplasmic reticulum 
to achieve muscle relaxation. This calcium pump has been 
reported to have a cardiac and slow skeletal muscle-spe-
cific isoform, SERCA2a, and the switch to the ubiquitous 
isoform, SERCA2b, leads to impairment of the contrac-
tile function of the heart in mice (Ver Heyen et al. 2001) 
(Fig. 5b).
Titin is a giant sarcomeric protein responsible for the 
generation of passive tension by binding to myosin and 
myosin-binding protein C, enabling muscle flexibility and 
extensibility. Titin is known to undergo AS involving its 
364 exons (Gigli et al. 2016; Zhu et al. 2016), and although 
a great number of titin isoforms can be generated, the adult 
cardiac muscle expresses two classes, whose ratios define 
the stiffness provided to the cardiomyocyte. The N2BA 
titin isoform is larger and contains additional spring ele-
ments that provide lower passive tension and more com-
pliance to the cardiomyocyte, while the N2B isoform is 
smaller and stiffer, comprising 60–70% of adult human car-
diac titin (Gigli et al. 2016). Moreover, AS of the titin gene 
has been linked to the regulatory activity of RNA binding 
motif protein 20 (RBM20), described as a regulator of car-
diac AS and whose mutations have been associated with 
human dilated cardiomyopathy (Guo et al. 2012; Maatz 
et al. 2014; Zhu et al. 2016). Alterations in titin isoform 
balance were found during development of rat cardiac mus-
cle, with N2BA levels decreasing and N2B levels increas-
ing after birth (Opitz et al. 2004; Zhu et al. 2016). Also, 
a study on the expression of cardiac titin in patients with 
dilated cardiomyopathy reported alterations at the isoform 
ratio level favouring the more compliant N2BA isoform, 
with a consequent decrease in passive myocardial stiffness 
(Nagueh et al. 2004; Gigli et al. 2016) (Fig. 5b).
In both ends of the sarcomere, actin filaments are 
attached to a filamentous, proteic disc called the Z-line 
(Seeley et al. 2006). The LIM domain-binding protein 3 
(LDB3) plays a role in muscle function by promoting sar-
comere Z-line stability during contraction and its develop-
mentally regulated isoforms are cardiac or skeletal muscle-
specific (Cheng et al. 2011; Zhu et al. 2016). Also, a recent 
study focusing on splicing transitions from embryonic to 
adult muscle involved evaluating the effect of CELF1 re-
expression in adult mouse cardiomyocytes and reported AS 
alteration in trafficking genes from adult to fetal patterns, 
resulting in multiple cardiac defects, namely, at the levels 
of T-tubule function, leading to impairment of the excita-
tion–contraction coupling, calcium balance and force gen-
eration (Giudice et al. 2014, 2016).
Myotonic dystrophy (DM) encompasses a group of 
genetically determined multisystemic disorders that com-
promise skeletal muscle function and are the most com-
mon cause of muscular dystrophy (Lee and Cooper 2009; 
Pistoni et al. 2010). Myotonic dystrophy type I (DM1) 
leads to progressive weakness, cardiac conduction defects 
and insulin resistance, being characterised by a repeated 
CTG sequence in the 3′ UTR of the dystrophia myotonica 
protein kinase (DMPK) gene concomitant with massive 
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alterations in AS patterns. The RNA resulting from the 
repeated CTG sequences forms a double-stranded hairpin 
structure in vitro that resembles the binding sites for some 
RBPs and sequestrate MBNL proteins to nuclear foci, 
accompanied by an increase in CELF1, which together 
contribute to the disruption of the normal adult muscle AS 
pattern, with embryonic-specific muscle isoforms being 
produced instead (Pistoni et al. 2010; Llorian and Smith 
2011). Some of the alterations in the splicing programme 
in DM1 are related to its symptoms, such as the aberrant 
splicing of the skeletal muscle-specific chloride channel 1 
(CLCN1), containing a premature STOP codon that leads 
to its downregulation in association to myotonia, or the 
increase of skipping of exon 11 of insulin receptor 1 (IR1), 
leading to insulin resistance (Savkur et al. 2001; Mankodi 
et al. 2002; Lee and Cooper 2009; Pistoni et al. 2010).
Moreover, an RNA-seq study on postnatal AS transitions 
during heart development performed in mouse cardiomyo-
cytes and cardiac fibroblasts reported that most alterations 
occurred before postnatal day 28, with an enrichment of 
AS transitions in genes related to vesicular trafficking and 
membrane alterations. This is consistent with the early life 
acquirement of an appropriate heart function, associated 
with proper membrane organisation, including correct ion 
channel functioning and ligand uptake, contributing to cor-
rect excitation/contraction coupling. Also, a substantial 
fraction of the AS events related to these transitions were 
enriched in binding motifs for CELF1, suggesting a direct 
mechanism for postnatal cardiac splicing regulation. To test 
the hypothesis of CELF1-regulated AS having a role in the 
assembly of the excitation–contraction apparatus, namely, 
in the invagination of the T-tubules, Giudice and colleagues 
induced re-expression of CELF1 in adult animals which 
was found to trigger important alterations in cardiac func-
tion in three different tests, with the T-tubule structure 
mimicking the one from postnatal days 10–15 (Giudice 
et al. 2014).
The RNA-binding protein RBM24 has been recently 
identified as a regulator of a large number of muscle-
specific AS events. Its inactivation in mouse led to severe 
malfunctions and deaths between embryonic days 12.5 and 
14.5 with great loss in sarcomeres of cardiomyocytes (Yang 
et al. 2014). The expression of RBM24 regulated muscle-
specific AS by binding to an intronic splicing enhancer in 
the vicinity of target muscle-specific exons, overcoming 
their repression by other splicing factors. RBFOX1 has 
been reported to co-regulate, together with MBNL1, mus-
cle-specific AS (Klinck et al. 2014; Conboy 2016). RBFOX 
protein family deregulations have been associated with car-
diac diseases, with decreased expression levels of RBFOX1 
found in human and mouse heart failure (Gao et al. 2016). 
Also, Wei and colleagues recently showed, in rodents, that 
transverse aortic constriction, modelling compensation and 
posterior decompensation mechanisms involved in heart 
failure, leads to decreased levels of RBFOX2, with conse-
quent splicing alterations, suggesting it may function as a 
pressure overload sensor (Wei et al. 2015). RBFOX1 and 
RBFOX2 are also involved in the regulation of AS events 
in Myocyte Enhancer Factor 2D (Mef2D) in mouse, switch-
ing the ubiquitous isoform to the one that activates the late 
muscle gene expression programme during myogenesis 
(Runfola et al. 2015).
Alternative splicing plays a major role in the specificity 
of striated muscle function and cardiac and skeletal mus-
cle disorders have been associated with altered isoform 
ratios or global loss of the adult muscle-specific AS pro-
files. However, knowledge on the processes that lead the 
identified patterns is still poor and further research on the 
modes of interaction of the different AS regulators shown 
to have a muscle-specific activity may provide new insights 
into these mechanisms, with potential relevant clinical 
applications.
Alternative splicing in the immune system
The immune system is composed of cells and molecules 
responsible for protection from infectious diseases and 
comprises both a rapid and general response, innate immu-
nity, and a more specific response, adaptive immunity, 
which develops as a response to infection. AS has been 
shown to contribute for the fine-tuning of both responses. 
For instance, Toll-like receptor signalling pathways, 
involved in innate immunity, are regulated by AS and alter-
native polyadenylation, as reviewed in (Carpenter et al. 
2014). As for adaptive immunity, AS plays a crucial role 
in ensuring the needed diversity and flexibility, as will be 
discussed in this section. The main effectors of the adaptive 
immune response are lymphocytes, which can be divided in 
two main groups: B cells and T cells. While the former are 
responsible for the production of antibodies, which recog-
nise microbial antigens and both neutralise them and mark 
them for destruction, the latter promote the destruction of 
intra- and extracellular microbes and help B cells in anti-
body production (Abbas et al. 2014).
It is essential that lymphocytes correctly distinguish 
between host and pathogens, reacting only to pathogenic 
antigens. Tolerance to self-antigens is referred to as self-
tolerance and is assured by elimination or receptor editing 
of self-reactive lymphocytes, mainly during maturation. 
Rearrangement of T-cell receptor (TCR) or immunoglob-
ulin (IG) locus genes and somatic hypermutation of the 
immunoglobulin variable region result in a vast repertoire 
of receptors, which are later exposed to self-antigens to 
eliminate or modify self-reactive ones. Medullary thymic 
epithelial cells (mTECs) are responsible for self-antigen 
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presentation to immature T cells and possess the unique 
ability of expressing a large fraction of all the self-anti-
gens of the host, including tissue-specific ones (Derbinski 
et al. 2001). This promiscuous expression is controlled by 
the autoimmune regulator (AIRE) protein (Anderson et al. 
2002) and has been shown to be further expanded by AS, as 
well as by RNA editing. mTECs were shown to have more 
alternatively spliced genes and express at least as many 
splice junctions per gene for most genes, including tissue-
specific ones, as all other tissues and cell types analysed 
(Danan-Gotthold et al. 2016). Indeed, while the diversity 
generated by AS throughout host tissues poses a challenge 
to the immune system, it seems to be extensively used by 
mTECs in an attempt to comprehensively represent all the 
host’s self-antigens.
After maturation, AS also plays an important role in 
lymphocyte activation. Both B- and T-cell activations result 
in extensive changes to gene expression and AS. It has been 
suggested that transcription factors controlled by BLIMP1 
repress the B-cell specific and activate the plasma cell-
specific gene expression programme, promoting matura-
tion of B cells into antibody-releasing plasma cells (Turner 
et al. 1994; Shaffer et al. 2002; Minnich et al. 2016). Even 
though AS changes in these cells are less clearly under-
stood, a recent study, profiling the transcriptional response 
of B cells to activating stimuli, indicates that AS, namely, 
alternative exon usage, affects a wide range of genes, with 
an enrichment in those with signalling and receptor func-
tions (Zhang et al. 2016). A classic example of such splic-
ing changes can be found in the AS of the Ig heavy chain, 
encoded by the IGH locus, at the 3′ end, resulting in two 
distinct isoforms: a membrane-bound antigen receptor and 
a secreted antibody (Rogers 1980; Early et al. 1980b), the 
latter being more expressed upon B-cell activation (Melch-
ers and Andersson 1973; Lamson 1984). More recently, 
hnRNPL-like (hnRNPLL) has been shown to directly 
associate with IGH mRNA and to be more expressed in 
plasma cells than in B cells, along with Elongation Factor 
for RNA-Polymerase II, ELL2 (Benson et al. 2012). HuR, 
a splicing factor encoded by ELAVL1, has also been shown 
to play a role in the splicing of several hundreds of tran-
scripts, mainly those involved in glycolysis, the citric acid 
(TCA) cycle and oxidative phosphorylation, all pathways 
upregulated following B-cell activation (DeMicco et al. 
2015; Diaz-Muñoz et al. 2015). Furthermore, Diaz-Muñoz 
and colleagues show that HuR is needed for B-cell prolif-
eration and differentiation into plasma and memory B cells, 
as well as class-switching to produce antibodies other than 
IgM and IgD (Diaz-Muñoz et al. 2015).
T cells also undergo global changes in the AS pro-
gramme upon activation (Martinez et al. 2012), which 
start by affecting genes involved in T-cell effector func-
tions and later genes that are relevant for homeostasis and 
immunologic memory (Ip et al. 2007), as shown in Fig. 6. 
Early AS changes affect, for instance, the CD44 gene (Arch 
et al. 1992), encoding for a cell-adhesion molecule involved 
in T-cell homing (DeGrendele et al. 1997) or, as recently 
discovered, MALT1, responsible for channeling TCR sig-
nalling to the IKK/NF-κB signalling pathway. Inclusion of 
MALT1 exon 7, containing a TRAF6-binding domain that 
renders the protein more active, is negatively regulated by 
hnRNPU and induced by TCR signalling (Meininger et al. 
2016). An increase in the expression of splicing regula-
tors upon T-cell activation has also been reported, such as 
hnRNP LL (Topp et al. 2008), CELF2 (Mallory et al. 2011) 
or SRSF1 (Moulton and Tsokos 2010), as well as phos-
phorylation of several splicing factors (Mayya et al. 2009). 
Some later stage splicing alterations act as feedback mech-
anisms, avoiding hyperactivity of the immune response 
and ensuring homeostasis, as is the case of CTLA4 (Mag-
istrelli et al. 1999) and PTPRC transcripts. PTPRC encodes 
the transmembrane tyrosine phosphatase CD45, critical 
for TCR signal transduction and, therefore, T-cell activa-
tion (Trowbridge and Thomas 1994). A long isoform is 
expressed in naïve T cells, containing either one or two 
of the alternative exons 4, 5, and 6, but, upon activation, 
PTPRC splicing is altered and isoforms containing none of 
the alternative exons are expressed (Beverley et al. 1988, 
1992; Merkenschlager and Beverley 1989). These shorter 
isoforms are more prone to dimerisation (Xu and Weiss 
2002), inhibiting CD45 phosphatase activity and resulting 
in lower TCR signal transduction. In naïve T cells, splic-
ing of PTPRC is regulated by the hnRNPL (Rothrock et al. 
2005) and SRSF1 proteins (Motta-Mena et al. 2010), while 
upon T-cell activation, hnRNPLL is expressed and induces 
repression of exons 4 (Oberdoerffer et al. 2008; Topp et al. 
2008) and 6 (Preussner et al. 2012). Furthermore, PTB-
associated splicing factor (PSF) is phosphorylated upon 
T-cell activation and represses the three variable exons 
(Melton et al. 2007).
In addition to the mentioned feedback mechanisms, 
immune activity is controlled by other mechanisms, such 
as apoptotic cell death, to avoid autoimmunity and assure 
T-cell homeostasis. The roles played by apoptosis include 
elimination of autoreactive T cells during maturation in 
the thymus and peripheral organs (central and peripheral 
T-cell tolerance), elimination of T cells activated for long 
in peripheral organs and also termination of the immune 
response (Abbas et al. 2014). Several genes involved in 
apoptosis are alternatively spliced, such as FAS, which 
encodes a death receptor. Skipping of its exon 6, contain-
ing the transmembrane domain, leads to the production 
of a soluble protein; inclusion of that exon results in a 
membrane receptor that can trigger signalling pathways 
leading to cell death (Hughes and Crispe 1995). This 
exon skipping event is regulated by TIA-1 and TIAR 
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hnRNPs in a feed-forward mechanism (Izquierdo et al. 
2005; Izquierdo and Valcárcel 2007). The importance of 
apoptotic regulation in the immune system is highlighted 
by the fact that higher levels of the soluble, anti-apoptotic 
FAS isoform are detected in patients with systemic lupus 
erythematosus (SLE) and mice injected with this isoform 
display autoimmune diseases (Cheng et al. 1994).
Deregulation of splicing events that are necessary for 
normal function of the immune system often leads to a 
wide range of diseases, from which we highlight auto-
immune diseases. These usually result from defective 
self-tolerance or regulation, due to impaired deletion of 
autoreactive lymphocytes, or low numbers of cells that 
regulate the immune response, such as regulatory T cells 
(Abbas et al. 2014).
Several SNPs affecting genes with relevant roles in the 
immune system have been described as leading to aber-
rant splicing patterns. An SNP in exon 4 of the aforesaid 
PTPRC gene, encoding for CD45, leads to the inclusion of 
that exon by disturbing an exonic splicing silencer. While 
the isoform lacking variable exons is expressed in activated 
T cells, to regulate activity, this polymorphism resulting in 
increased expression of the longer isoform is one of those 
linked to multiple sclerosis (MS) (Lynch and Weiss 2001; 
Evsyukova et al. 2010). Several other genes involved in 
immune system function have SNPs linked to autoimmune 
diseases. For instance, an SNP affecting a branch point 
site in the BANK1 gene, encoding for a protein involved in 
B-cell receptor signalling, induces skipping of the consti-
tutive exon 2 and has been linked to SLE (Kozyrev et al. 
2008). Other reports have linked skipping of exon 9 of 
Fig. 6  Isoform shifts following T-cell activation. T-cell activation 
upon antigen recognition leads to global changes in AS, from which 
the inclusion of MALT1 exon 7 and CD44 variable exons are high-
lighted. In the case of MALT1, inclusion of TRAF-binding domains 
contained in its exon 7 leads to a higher recruitment of TRAF6 to 
the CARMA1-BCL10-MALT1 (CBM) signalling complex, which 
facilitates IKK activation (Meininger et al. 2016). This results in an 
enhancement of signalling pathways downstream of TCR signalling 
and promotion of T-cell activation. As for the transmembrane gly-
coprotein CD44, ten variable exons are located in the extracellular 
domain of the protein, which can be excluded or included in different 
combinations, leading to differences in binding affinity to extracellu-
lar matrix components, namely, hyaluronic acid (Naor et al. 1997). 
While in resting T cells the CD44 variable exons are skipped (iso-
form CD44s), these are included upon activation (Arch et al. 1992). 
Even though the importance of this event is not yet clear, CD44 is 
known to be involved in T-cell homing (DeGrendele et al. 1997) 
and survival (Baaten et al. 2010). Later stage changes in alternative 
pre-mRNA splicing often impact genes involved in homeostasis and 
immunologic memory, from which we take CD45 and CTLA4 as 
examples. Skipping of alternative exons 4–6 of CD45, results in the 
production of an isoform more prone to dimerisation, which inhib-
its the role of CD45 in TCR-signalling transduction. CTLA4, on the 
other hand, competes with CD28 for ligand binding (van der Merwe 
et al. 1997), and delivers inhibitory signals that counteract the co-
stimulatory signal conferred by CD28 (Krummel and Allison 1995). 
Upon activation, CTLA4 expression is increased and exon 3, encod-
ing a transmembrane domain, is included (Oaks et al. 2000), drasti-
cally increasing the expression of CTLA on the cell surface and 
empowering the T-cell inhibitory signal. TCR T-cell receptor, TMD 
transmembrane domain
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protein-tyrosine phosphatase sigma (PTPRS) to ulcera-
tive colitis (Muise et al. 2007) and reduced splicing effi-
ciency of intron 1 of inositol 1,4,5-trisphosphate 3-kinase C 
(ITPKC) to Kawasaki disease (Onouchi et al. 2008).
Interestingly, AS has also been proposed to generate 
epitopes to which the organism has not been tolerized. Cen-
tral tolerance only covers a set of isoforms but, in autoim-
munity-prone conditions, expression of the remaining, non-
tolerized isoforms increases, which may trigger an immune 
response (Ng et al. 2004). One example is the myelin pro-
teolipid protein (PLP), present in either a longer isoform 
or a shorter one, lacking exon 3B. PLP is expressed in the 
thymus, but this expression is restricted to the short iso-
form, so the host does not acquire tolerance to exon 3B. In 
pathogenic conditions, damage is exerted to myelin and the 
longer isoform is exposed, which may trigger an autoim-
mune reaction that contributes to MS (Klein et al. 2000).
Alternative splicing has been shown to provide an extra 
layer of regulation in the immune system, from the repro-
gramming of B and T cells upon activation to the genera-
tion of the diversity that characterises this complex and 
dynamic system. Disruption of this regulatory layer by 
SNPs can lead to diseases, particularly to autoimmunity, 
which underscores the importance of unveiling new mecha-
nisms and alterations to splicing regulation in the context 
of the immune system.
Alternative splicing and transcriptomic crosstalk 
with human microbiota
Infectious diseases are one of the main causes of mortality 
worldwide and the problem increases with the development 
of drug-resistant pathogens. A comprehensive understand-
ing of the underlying mechanisms of infections, particu-
larly the molecular interactions between the host and the 
infectious agents, is critical to the identification of novel 
virulence factors and host–response pathways essential to 
assess and design more effective diagnostic and therapeutic 
strategies.
During the course of an infection, pathogens subvert cel-
lular mechanisms of the host organisms for replication and 
survival, while infected host cells respond through a cas-
cade of changes at the transcriptomic and metabolic lev-
els. Interestingly, the recent finding of “nucleomodulins”, 
bacterial proteins able to act directly in the nucleus of host 
cells (Bierne and Cossart 2012), indicates that those patho-
genic microorganisms have evolved mechanisms to actively 
manipulate nuclear regulatory pathways and reprogramme 
host gene expression to their advantage.
Moreover, emerging evidence suggests that host manip-
ulation by pathogens may involve alterations in the AS 
programme of infected cells. Using an integrated approach 
of stable isotope labelling with aminoacids in cell culture 
(SILAC), 2-DE gels and matrix-assisted laser desorption/
ionisation (MALDI) mass spectrometry analyses, Holland 
and colleagues (Holland et al. 2011) discovered significant 
changes in the phosphoproteome of gastric epithelial cells 
upon infection with the Gram-negative bacterium Helico-
bacter pylori, which causes chronic inflammation of the 
human gastric mucosa. Interestingly, almost one-third of 
the identified proteins appeared associated with the spli-
ceosome or RNA splicing and several SR proteins exhib-
ited alterations in phosphorylation and/or abundance. These 
results lead the authors to speculate that modifications in 
cellular splicing patterns associated with H. pylori infection 
could be the cause of changes in activity and specificity of 
cellular regulators such as kinases and tumour suppressors, 
thereby contributing to cellular dysfunction and transfor-
mation. Bacterial interaction with components of the AS 
machinery in host cells also occurs upon infection with 
Shigella, a highly adapted human pathogen that causes bac-
illary dysentery. Shigella’s invasion within epithelial cells 
involves the delivery of a subset of effectors directly into 
the cytoplasm of host cells using a complex bacterial struc-
ture called type III secretion. One of these protein effectors 
is IpaH9.8, shown to translocate into and accumulate within 
the nucleus, where it disrupts splicing activity upon binding 
to the U2AF35 splicing factor and reduces the expression 
of chemokines and cytokines involved in neutrophil recruit-
ment and proinflammatory responses (Okuda et al. 2005). 
Based on these observations, it was proposed that the role 
of IpaH9.8 in bacterial infection is to modulate the acute 
innate immune response through the regulation of RNA 
synthesis, thus promoting efficient colonisation within 
the host cells. Orthologs of IpaH9.8 have also appeared to 
translocate into the nucleus of host cells, such as SspH1 of 
Salmonella enterica (the major cause of salmonellosis) and 
YopM of Yersinia pestis (responsible for plague) (Haraga 
and Miller 2003; Benabdillah et al. 2004), although their 
association to the host’s transcriptional regulation and AS 
programmes is still to be elucidated.
Viruses are other examples of how pathogens can 
take advantage of the splicing machinery in the infected 
cells for their own benefit. It has been shown that ade-
novirus, HIV and herpesvirus depend on host splic-
ing modulators for viral RNA processing (Muhlemann 
et al. 2000; Fukuhara et al. 2006; Nojima et al. 2009). 
Moreover, viral proteins can modulate splicing of cellu-
lar pre-mRNAs that in turn regulate virus propagation. 
Herpes simplex virus type 2 (HSV-2), for instance, was 
found to modify the expression of promyelocytic leu-
kaemia (PML) isoforms in host cells through the activ-
ity of ICP27 (Nojima et al. 2009), a viral protein known 
to interact and colocalise with cellular splicing regula-
tors such as SR proteins, snRNPs and other spliceosome 
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components (Sandri-Goldin and Hibbard 1996; Bryant 
et al. 2001; Sciabica et al. 2003). Furthermore, ICP27 
has been involved in the splicing regulation of viral 
genes critical for pathogenesis through modulation of 
intron retention events (Sedlackova and Rice 2008). Fur-
ther analyses revealed that, in fact, ICP27 also induces 
intron retention within the PML transcript upon binding 
to the 3′ splice site of intron 7a, resulting in an isoform 
switching from PML-II to PML-V, which in turn affected 
HSV-2 replication. As PML has been proposed to con-
tribute to intrinsic antiviral defence but also to promote 
efficient viral propagation (Chee et al. 2003; Ching et al. 
2005), PML isoform switch was proposed to potentially 
contribute to the mechanisms controlling these antagonis-
tic functions of PML in the host response to viral infec-
tion. A recent RNA-seq analysis of the HSV-1 infected 
host transcriptome of human primary fibroblast BJ cells 
revealed profound changes in both gene expression and 
AS in host cells (Hu et al. 2016). Several splicing factors, 
such as PABPC1, YBX1, XAB2, and ZFP36, were shown 
to be upregulated and more than a thousand AS events 
appeared dysregulated, including events that contribute 
to the activation of the cellular stress response. How-
ever, it is still unclear how exactly HSV-1 infection led 
to changes in cellular AS processes. To note, about 22% 
of the alternatively spliced events identified in this study 
correspond to intron retention events. It is possible that at 
least part of these alterations can be due to the activity of 
ICP27, as HSV-1 ICP27 has also been shown to promote 
intron retention in infected cells (Sedlackova and Rice 
2008). Importantly, the transcriptomic analysis of HSV-
1-infected cells revealed perturbations not only at the 
level of AS, but also in alternative polyadenylation and 
general isoform composition, suggesting that the viral 
modulation of host RNA processing is more extensive 
and may be, as in the case of transcriptional regulation, a 
critical component of the complex pathogen-host molec-
ular interactions.
Several lines of evidence suggest that tumourigenesis 
caused by tumour viruses is also mediated by cellular and 
viral AS programmes. Some known tumour-promoting 
protein isoforms are produced through AS of viral onco-
gene transcripts (Zheng 2010; Young et al. 2011; Ajiro and 
Zheng 2015) and numerous cellular mechanisms have been 
shown to modulate this oncogenic viral splicing (Wang and 
Manley 1995; Rosenberger et al. 2010; McFarlane et al. 
2015; Graham and Faizo 2016). More recently, RNA-seq 
combined with de novo transcriptome assembly in cul-
tured cells infected with the oncogenic human papilloma-
virus HPV16 revealed the upregulation, in infected cells, of 
the splicing factor CELF3 as well as several differentially 
expressed novel human transcripts which appeared associ-
ated with well-known cellular pathways altered in cancer 
such as the MAPK and the VEGF signalling (Xu et al. 
2016). Based on this evidence, it has been proposed that 
viral AS represents a promising therapeutic target in the 
treatment of viral-induced tumours, such as in the context 
of other non-tumourigenic viral infections where therapeu-
tic strategies targeting the splicing machinery have already 
been tested (Hernandez-Lopez and Graham 2012).
Traditionally, the analysis of gene expression patterns in 
host cells and pathogens has been carried out using micro-
arrays or reverse transcription PCR of a single species at 
a time. However, the advent of systems biology methods 
that integrate multi-omic data is transforming our under-
standing of infectious diseases by considering the host–
pathogen molecular interface as a unified module. Among 
these novel approaches, the development of the dual RNA 
sequencing (dual RNA-seq) technique has allowed the 
simultaneous analysis of transcriptomes of host cells and 
intracellular pathogens (Hernandez-Lopez and Graham 
2012; Westermann et al. 2012; Rosani et al. 2015; Aprianto 
et al. 2016) (see Fig. 7), revealing cascades of changes in 
Fig. 7  Dual RNA-seq workflow. Due to the relative difference in 
total RNA abundance between host cells and pathogen in most infec-
tion models, deep sequencing is required to obtain a more precise 
profiling of transcriptomic changes associated with the infection pro-
cess. This strategy allows the transcriptomic analysis of both host and 
pathogen at different time points during infection, with the discrimi-
nation between the two taking place only at the bioinformatics stage
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gene expression but also unpredicted functions of pathogen 
genes in regulating other RNA-synthesis processes such 
as the expression of long noncoding RNAs (Westermann 
et al. 2016). We anticipate that dual RNA-seq analysis will 
be particularly important not only in the characterisation 
of novel regulatory mechanisms of AS and other post-tran-
scriptional modifications during the course of infection, but 
also in the assessment of the contribution of human micro-
biota to normal physiology and disease predisposition.
Alternative splicing in cancer
There is a growing recognition of the key role played by 
aberrant splicing in tumourigenesis, cancer progression and 
resistance to therapy. Accumulating evidence shows that 
dysregulated splicing is frequently associated with the inac-
tivation of tumour suppressors and the activation of onco-
genes. A recent systematic analysis of SNVs across six 
cancer types profiled in The Cancer Genome Atlas (TCGA) 
Project revealed that SNVs causing intron retention were 
enriched in tumour suppressors and that the vast majority 
of these events generated premature termination codons 
leading to nonsense-mediated decay, thus suggesting that 
intron retention is a common mechanism of tumour-sup-
pressor inactivation (Jung et al. 2015). This notion was 
further validated by a TCGA transcriptomic data analysis 
that revealed increased levels of intron retention relative to 
normal tissue controls across most cancer types, suggesting 
that an abundance of intron-containing mRNAs in tumour 
cells may increase the transcriptional diversity of many 
cancers (Dvinge and Bradley 2015).
Aberrant splicing also participates in the activation of 
oncogenes by producing splice variants with novel prolif-
erative or survival abilities. Recent genomic characterisa-
tion of different types of cancer revealed “spliceosomal 
mutations” that affect splice site choice as well as exon rec-
ognition motifs, which induce isoform switching or even 
entirely new splice variants specific to tumour cells (Har-
bour et al. 2013; Martin et al. 2013; Alsafadi et al. 2016). 
In addition, alterations in splicing regulatory mechanisms 
can result in the imbalanced expression of splice variants 
of the same gene playing antagonistic functional roles and 
thus the associated protein interaction network can also 
be affected (Boise et al. 1993; Cheng et al. 1994). Several 
examples of this splicing-driven functional inversion in 
cancer occur in genes regulating pro- and anti-apoptotic 
signalling, such as the case of caspase-9 expressing a short 
splice variant (caspase-9S) that inhibits full-length cas-
pase-9-dependent apoptotic signalling by interfering with 
its binding to Apaf-1 and the formation of the so-called 
“apoptosome” complex (Seol and Billiar 1999), the long 
isoforms of BCL-X (BCL-XL) and APAF1 (APAF1L) 
known to inhibit programmed cell death, whereas their 
short isoforms (BCL-XS and APAF1S) promote it (Boise 
et al. 1993; Walke and Morgan 2000), the proapoptotic 
long isoform of caspase-2 (Casp-2L) that antagonizes the 
anti-apoptotic short isoform (Casp-2S) (Droin et al. 2001), 
and the complex pattern of pro- and anti-apoptotic isoforms 
of the tumour-suppressor TP73 gene generated through the 
use of alternative promoters and AS (Stiewe and Pützer 
2002).
Moreover, alterations in the gene expression of multiple 
splicing factors and their regulators represent another level 
of dysregulation in the AS programme in cancer. Interest-
ingly, the same splicing factor can appear upregulated in 
some cancers and downregulated in others (see Fig. 8), 
indicating that the regulatory pattern of its expression 
is likely to be distinct among tumour types. Examples of 
well-characterised families of splicing factors differentially 
expressed across several types of cancer are SR proteins, 
including SRSF1, SRSF3 and SRSF6 (Karni et al. 2007; 
Jia 2010; Anczuków et al. 2012; Jensen et al. 2014), and 
hnRNPs, such as hnRNPA1, hnRNPA2 and PTBP1 (David 
et al. 2010; Clower et al. 2010). Several important roles in 
cancer development have been recently found to be played 
by other splicing factors, such as the function of FOX2, 
RBM4, and CELF2 as tumour suppressors (Ramalingam 
et al. 2012; Wang et al. 2014; Yong et al. 2016), the onco-
genic effect of CELF1 (House et al. 2015), or the regula-
tion of SRSF3 splicing patterns by PTBP1 and PTBP2 
(Guo et al. 2015). The function of these and other cancer-
associated splicing factors is reviewed in detail in (Fu and 
Ares 2014) and (Dvinge et al. 2016).
Ultimately, altered expression of splicing factors and 
aberrant splicing programmes in general contribute to 
critical aspects of the so-called hallmarks of cancer, which 
represent biological capabilities acquired during tumouri-
genesis and cancer progression. They include sustained 
cell proliferation, the evasion from growth suppressors 
and apoptosis, the deregulation of cellular metabolism, 
the avoidance of immune destruction, and the activation of 
angiogenesis, invasiveness, and metastasis (Hanahan and 
Weinberg 2011). In fact, aberrant splicing itself has been 
proposed as a novel hallmark of cancer (Ladomery 2013).
SRSF1 splicing factor and its associated kinase SRPK1, 
for instance, have been implicated in the regulation of 
splicing events with prominent roles in several oncogenic 
signatures, including the retention of intron 4 in the cyc-
lin D1b splice variant that promotes cellular transformation 
(Olshavsky et al. 2010), splicing events conferring escape 
from apoptosis such as the inclusion of BIM exon 3 or exon 
4 in Caspase 9 (Shultz et al. 2011; Leu et al. 2012), isoform 
switches in the vascular endothelial growth factor (VEGF) 
with pro and antiangiogenic functions (Nowak et al. 2010), 
and inclusion of the exon 3b in the GTPase Rac1 and 
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skipping of exon 11 in the tyrosine kinase receptor RON, 
both events known to induce cell dissociation, mobility and 
invasion in several cancer types (Ghigna et al. 2005; Gon-
çalves et al. 2014).
Apart from these and other well-characterised altera-
tions in AS patterns affecting key components of cancer 
hallmarks, such as PT53, hTERT, EGFR, CD44, KLF6, 
FAM3B, MENA, NUMB, or BRAF, which have been exten-
sively reviewed before (David and Manley 2010; Bonomi 
et al. 2013; Oltean and Bates 2014; Sveen et al. 2016), novel 
insights into tumour-associated dysregulation of splicing and 
its biological consequences have been recently described. 
One case is the functional interplay between splicing mecha-
nisms and transcription modulation by transcription factors 
activity, which is now emerging as an important regulatory 
axis in cancer cell biology. A new general splicing-based 
regulation of tumour growth has been proposed based on the 
observation that an isoform switch of the transcription fac-
tor TEAD4 modulates the expression of components of the 
Hippo-YAP pathway, known as a core regulator of cell cycle, 
proliferation and apoptosis (Qi et al. 2016). The MYC tran-
scription factor, overexpressed in most human cancers and 
associated with highly proliferative tumours and poor prog-
nosis, was found to regulate the maintenance of a fully func-
tional splicing machinery by controlling the transcription of 
snRNP components. Through this mechanism, MYC ensures 
proper RNA processing and consequent expression of full-
length proteins that sustain cancer cell survival and prolifera-
tion such as ATR, EP400 and DVL1 during lymphomagen-
esis (Koh et al. 2015). To note, SRSF1 was also found to 
regulate MYC by promoting the inclusion of exon 12a in the 
tumour-suppressor BIN1, known to bind MYC and reduce 
its oncogenic activity (Sakamuro et al. 1996).
The link between transcriptional regulation and the 
splicing programme in cancer also involves modifications 
at the level of high-order chromatin structure. Altered func-
tion of chromatin modifiers has been implicated in the dis-
ruption of proper RNA processing and splicing, such as the 
case of mutations in the histone methyltransferase SETD2 
in kidney tumours (Simon et al. 2014; Grosso et al. 2015). 
Similarly, the binding of alternatively spliced short iso-
forms of splicing factor SON near transcription start sites 
was found to inhibit mixed lineage leukaemia (MLL) com-
plex-mediated methylation of histone H3K4, a common 
landmark found at promoter regions of activated genes. 
Importantly, those short SON isoforms appeared markedly 
upregulated in acute myeloid leukaemia (Kim et al. 2016) 
and their overexpression enhances the growing capabil-
ity of hematopoietic progenitors in vitro. Based on these 
results, it was proposed that an increase in alternatively 
spliced short isoforms of SON induces aberrant transcrip-
tional initiation in leukaemia.
Moreover, a revealing contribution of AS to hypoxia-
dependent increase of genetic instability in cancer has been 
recently characterised (Memon et al. 2016). Conditions of 
low oxygen occurring within most solid tumours are asso-
ciated with poor patient outcome and resistance to therapy. 
In the study performed by Memon et al., hypoxic colorectal 
cancer cells exhibited systematic alterations in AS that con-
tributed to the control of protein levels by increasing intron 
retention, which in turn favoured the expression of non-
coding isoforms and a rapid decline in protein synthesis. 
Fig. 8  Alterations in the expression of splicing factors in cancer. A 
pan-cancer analysis using TCGA data revealed 132 splicing factors 
differentially expressed between tumour and normal samples (x-axis). 
Patterns of upregulation and downregulation across different tumor 
types (y-axis) are shown in green and violet gradients, respectively. 
The color intensity indicates the log2-fold change (log2 FC). Splicing 
factors are clustered into three groups according to the incidence of 
each expression pattern in the analysed tumours: frequently downreg-
ulated (left), frequently upregulated (right), and tendency to show an 
opposite pattern between the three kidney and the rest of tumor types 
(Opposing). The bar plot in the top indicates the frequency of tumor 
types with up-(green) or down-(violet) regulation for each factor. 
Kidney Chr, kidney chromophobe; Kidney RC, kidney renal clear cell 
carcinoma; Kidney RP, kidney renal papillary cell carcinoma; Lung 
Ad, lung adenocarcinoma; Lung Sq, lung squamous cell carcinoma. 
Image adapted with permission, from Sebestyén et al. (2016)
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Importantly, the increase in intron retention levels was 
observed in genes involved in specific pathways, including 
those associated with DNA damage response. These results 
reveal that changes in isoform usage under tumour hypoxia 
are the consequence of a coordinated reprogramming of 
AS.
The recent advent of genome-wide analyses of AS 
events in cancer has been revealing cases of global altera-
tions involving hundreds of differentially spliced tran-
scripts, as well as mutations and/or alterations in the 
expression of components of the core splicing machinery 
and regulatory splicing factors. In this regard, the molecular 
and clinical information contained in the TCGA repository 
has been a valuable tool to identify differences in splicing 
patterns between cancer and normal samples and between 
different tumour molecular subtypes (Brooks et al. 2014; 
Anczuków et al. 2015; Ryan et al. 2016; Dominguez et al. 
2016; Sebestyén et al. 2016; Shen et al. 2016). TCGA data 
were also used in systematic pan-cancer analyses, revealing 
a pool of splicing events commonly altered across different 
cancer types and splicing factors whose expression strongly 
associates to cancer-specific splicing signatures, such as 
that of RBFOX2, QKI, PTBP1, MBNL1/2 and CELF2 
(Sebestyén et al. 2015, 2016; Tsai et al. 2015; Danan-Got-
thold et al. 2015).
Given the large amount of information that TCGA and 
other sample collections provide, involving several types 
of omics data and associated clinical features, the chal-
lenge now is integrating this knowledge to identify cancer-
specific core regulatory mechanisms upstream of altered 
splicing networks and to characterise the functional signifi-
cance and cause-effect relationship between cancer-specific 
changes in AS and oncogenesis.
Splicing therapy
The previous sections of this review describe how misregu-
lation of AS, namely, through perturbation of trans-acting 
factors that can trigger widespread splicing defects and/
or disruptions in cis that can alter splice sites and other 
splicing sequence regulatory elements, can have an impact 
in human health (Garcia-Blanco et al. 2004). Moreover, 
according to the latest report of the Human Gene Muta-
tion Database, around 10% of human inherited diseases are 
due to single base-pair substitutions mutations located in 
splice sites (Stenson et al. 2009). However, this estimation 
does not take into account mutations in other splicing cis-
regulatory elements nor in the actual promoter or coding 
sequences of trans-acting factors, suggesting an even more 
prevalent role of splicing in human genetic diseases (Ward 
and Cooper 2009). Based on the above evidence, several 
therapeutic approaches based on modulation of splicing for 
different human diseases are being explored nowadays.
In fact, the great structural diversity of RNA and its lack 
of repair mechanism enhance the impact of therapeutics 
targeting it (Hermann and Westhof 1998). Thus, by lever-
aging the dynamic nature of RNA turnover, it is possible to 
time limit and modify the therapy according to individual 
responses (Douglas and Wood 2011).
One of the approaches vastly adopted to target splicing 
is the use of antisense oligonucleotides (ASOs). ASOs are 
synthetic molecules composed of nucleotides or their ana-
logues that bind to a nucleic acid molecule with a comple-
mentary sequence (Bauman et al. 2009). They can be used 
to target a splice site by blocking it and thereby alter its 
recognition by the spliceosome, redirecting splicing to an 
adjacent site (Havens and Hastings 2016). ASOs can also 
be used to prevent the binding of trans-acting regulatory 
splicing factors by targeting their binding sites (Havens 
et al. 2013; McClorey and Wood 2015). Diseases for which 
this therapy is being developed include spinal muscular 
atrophy (SMA), Duchenne Muscular Dystrophy (DMD) 
and amyotrophic lateral sclerosis (ALS). Most of SMA 
cases are linked to downregulation of the SMN1 gene and 
the aberrant splicing of exon 7 of the SMN2 gene, a nearly 
identical copy of SMN1. ASOs are being used to correct 
the aberrant splicing of exon 7 of SMN2 and promote its 
inclusion by binding to the unique GC-rich sequence 
located within the downstream intron, as illustrated in 
Fig. 9a (Singh et al. 2009; Osman et al. 2016). DMD cases 
are associated with mutations in the DMD gene that fre-
quently cause a deletion-induced frameshift in exon 51 by 
creating a premature termination codon that will produce 
a truncated and usually non-functional dystrophin protein 
(Havens and Hastings 2016). This commonly DMD-asso-
ciated deletion can be restored using ASOs to induce skip-
ping of exon 51 (Scotti and Swanson 2016). As for ALS, 
ASOs were designed to lower the mRNA levels of SOD1, 
whose mutation is responsible for 13% of familial ALS 
cases, by intrathecal administration and went through a 
phase I clinical trial (Miller et al. 2013). ASO therapies for 
SMA and DMD are also on clinical trials (Fletcher et al. 
2017; Aartsma-Rus and Krieg 2016).
Another method being developed for these disorders 
as well as others, such as cystic fibrosis and Huntington’s 
disease, is SMaRT (Spliceosome-mediated RNA trans-
splicing). It also relies on the correction of alterations at 
the post-transcriptional level by modifying the mRNA 
sequence through the introduction of an exogenous RNA 
in targeted cells to induce a splice event in trans between 
the exogenous RNA and the target endogenous pre-mRNA 
(Berger et al. 2016) (see Fig. 9b). This process generates 
a chimeric RNA with exons from the exogenous and the 
endogenous RNA free of mutations.
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However, ASOs and SMaRT techniques present some 
drawbacks. For instance, ASOs are not efficaciously deliv-
ered because they are subjected to nuclease susceptibil-
ity in circulation, leading to a short half-life (McClorey 
and Wood 2015). Moreover, negatively charged ones have 
a limited passive diffusion through the cell membranes 
(McClorey and Wood 2015). Nevertheless, research in the 
field keeps trying to find new methods to enhance ASOs’ 
delivery, especially in organs with difficult access such as 
the brain, where crossing the blood–brain barrier is a chal-
lenge. One method being explored to circumvent these 
problems is the use of cell-penetrating peptides (CPPs), 
small peptides able to carry peptides, proteins, nucleic 
acids and nanoparticles across the cellular membrane 
(Zahid and Robbins 2015). This technique made it indeed 
possible to enhance the correction of ATM aberrant splic-
ing causing ataxia-telangiectasia, a recessive neurogenetic 
disorder, by being able to deliver the ASO to the brain and 
cerebellum (Du et al. 2011). Delivery limitations have also 
promoted the discovery of small molecule modulators of 
splicing (Salton and Misteli 2016), identified as a good spli-
ceosome-targeting tool and that can be synthetic or derived 
from natural products as fungi, medicinal plants and bac-
teria (Martínez-Montiel et al. 2016). For instance, the spli-
ceosome SF3b subunit has been shown to be targeted by 
three bacterial natural products, pladienolide, herboxidiene 
and the FR901464 molecule, as well as by meaymicin, a 
synthetic analogue of FR901464 (Albert et al. 2009; Webb 
et al. 2013). They are all cytotoxic agents and are mostly 
recognised as antitumour agents (Salton and Misteli 2016; 
Kumar et al. 2016). In fact, E7107, a small molecule that 
also targets the spliceosome, has gone to a phase I clinical 
trial for treating solid tumours (Eskens et al. 2013). Moreo-
ver, new small molecules can be potentially found by high-
throughput screening approaches. Mandrasin, for instance, 
was found by screening a highly curated library of about 
72,000 drug-like small molecules using a high-throughput 
in vitro splicing assay, being shown to have the ability of 
inhibiting splicing in cultured human cell lines (Pawellek 
et al. 2014). Most small molecule modulators of splic-
ing affect important components of the spliceosome such 
as SF3b but others, known to inhibit protein acetylation 
and deacetylation, can affect RNA processing via stalling 
of spliceosome assembly (Kuhn et al. 2009; Bates et al. 
2017). For instance, borrelidin, an antifungal compound, 
was found to have an antiangiogenic activity in tumour 
and binds to the splicing protein FBP21, which is one of 
the structural proteins of the spliceosome (Woolard et al. 
2011). However, their lack of specificity and consequent 
potential to alter splicing of multiple unspecific genes lim-
its their employment in therapeutic strategies (Havens et al. 
2013).
Here, we have described the most prominent techniques 
being developed to manipulate splicing with therapeutic 
purpose, aware of the need for improvements at the levels 
of the delivery system of ASOs and the specificity of small 
Fig. 9  Splicing therapy methods. a Antisense oligonucleotides 
(ASOs) are being used for spinal muscular atrophy to correct the 
aberrant splicing of exon 7 of SMN2. The ASO binds to the unique 
GC-rich sequence located within the downstream intron to promote 
the exon 7 inclusion. b Spliceosome-mediated RNA trans-splicing 
(SMaRT) method relies on the correction of alterations at the post-
transcriptional level by modifying the mRNA sequence. An exog-
enous RNA is introduced in targeted cells to induce a splicing event 
in trans with the target endogenous sequence, generating a chimeric 
RNA with exons from the exogenous and the endogenous RNA free 
of mutations. 5′ss, 5′ splice site; 3′ ss, 3′ splice site; BPS, branching 
point site; PPT, polypyrimidine tract; pA, polyadenylation signal
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molecules. Moreover, AS is being progressively recognised 
as a promising therapeutic target, highlighting the need 
for a more profound understanding of the splicing-related 
mechanisms involved in disease conditions. In this respect, 
the PP1γ2, Nek2A-T, and NIPP1-T genes are currently 
being investigated as alternatively spliced targets for signal 
transduction therapeutics in male infertility (Fardilha et al. 
2004). Furthermore, in cancer, targeting components of 
spliceosome has also been suggested as a potential therapy. 
For instance, genetic or pharmacological inhibition of the 
spliceosome in vivo was shown to associate with an impair 
in survival, tumourigenicity, and metastatic proclivity of 
MYC-dependent cancers (Hsu et al. 2015).
The increasing knowledge about mechanisms of splic-
ing regulation will also provide new conceptual tools to 
improve the already known techniques or even to create 
novel treatment strategies for modulating splicing in dis-
ease contexts, unveiling splicing therapy as a tool for per-
sonalized medicine.
Concluding remarks
As once stated in Christopher Nolan’s film The Prestige 
(Nolan and Nolan 2006), “Every great magic trick consists 
of three parts or acts. The first part is called The Pledge. 
The magician shows you something ordinary (…).” In a 
cellular context, the spliceosome performs canonical intron 
excision. “The second act is called The Turn. The magician 
takes the ordinary something and makes it do something 
extraordinary.” In this case, the spliceosome is able to carry 
out splicing in alternative ways. “Now you’re looking for 
the secret… (…) That’s why every magic trick has a third 
act, the hardest part, the part we call The Prestige.” Indeed, 
AS has an outstanding ability to allow the expression of 
highly specialised condition- and tissue-specific isoforms 
that contribute to different essential functions in the com-
plex human physiology.
In this review, we describe how this is performed not 
only by the spliceosome but also with the assistance of 
other splicing regulators. However, a more comprehen-
sive understanding of how these molecules and networks 
interact to regulate global and tissue-specific splicing pro-
grammes is still required. It is, therefore, imperative to 
unveil these regulatory mechanisms to be at the forefront of 
molecular characterisation of tissue function and disease.
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